Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180748 | 0.83 | TTK (0.37) | SNCAUSP30DGAT1 | |
| SCHEMBL29855985 | 0.82 | DGAT1 (0.45) | USP30DGAT1 | |
| SCHEMBL4553845 | 0.82 | DGAT1 (0.45) | USP30DGAT1 | |
| SCHEMBL1922366 | 0.79 | DGAT1 (0.33) | SNCADGAT1 | |
| SCHEMBL2099862 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL4165224 | 0.74 | CXCR4 (0.34) | SNCADGAT1 | |
| SCHEMBL14674020 | 0.71 | SNCA (0.36) | SNCA | |
| SCHEMBL8083423 | 0.69 | TSHR (0.41) | SNCA | |
| SCHEMBL4264297 | 0.69 | SNCA (0.44) | SNCA | |
| SCHEMBL2099860 | 0.69 | DGAT1 (0.34) | USP30DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957215-B2 | Heteroaryl substituted benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | ASTRAZENECA AB (SE) | 2012-08-16 | — | — | US | disclosed |
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1981883-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | APP, MAPT, PSEN1 | SNCA 102/4885USP30 3199/4885DGAT1 1170/4885 |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | MAPT, APP, PSEN1 | SNCA 68/4885USP30 3529/4885DGAT1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.